Main > > >NEUROENDOCRINE TUMORS. (NETs.) *

GastroEntericPancreatic (GEP) NET.
Treat.: 177Lu-EdoTreotide.
(UnResectable.)
Status: Phase III.
Companion Diagnostics>
68Ga-EdoTreotide>AT,DE,FR Approval
Date: 2018. 05.25.
Lutetium-177>EU Approval Date: 2016.
08.04.
(*) Company; Patents; TradeMarks & Web-
Sites Available on Request.
UpDate: 2018. 11.24.




GastroEntericPancreatic (GEP) NET.
Treat.: 177Lu-OxodoTreotide.
[Somatostatin Receptor (SR)+].
>Companion Diagnostics>
68Ga OxodoTreotide>Approved in EU, USA
EU Approval Date : 2017. 09.29.
USA Approval Date: 2018. 01.26.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.25.




GastroEntericPancreatic (GEP) NET.
Treat.: Lanreotide Acetate Inj.
(Metastatic; NonResectable)
JP Approval Date : 2017. 07.03.
USA Approval Date: 2014. 12.16.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2018. 11.25.




GastroIntestinal (GI) NET. Treat.: Everolimus Tablets.>UnResectable.
EU Approval Date : 2016. 06.02.
USA Approval Date: 2016. 02.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.23.




Lung NET. Treat.: Everolimus Tablets. >UnResectable.
EU Approval Date : 2016. 06.02.
USA Approval Date: 2016. 02.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.23.




Pancreatic NET. Treat.: Everolimus Tablets.>UnResectable.
EU Approval Date : 2011. 09.05.
USA Approval Date: 2011. 05.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.23.




Paraganglioma/PheoChromoCytoma NET.
Treat.: Iobenguane I 131 Inj. IV Use.
USA Approval Date: 2018. 07.30.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.25.


>NEUROENDOCRINE TUMORS. (NETs.) *'s products
This section has no products